Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

2 hours ago 2

Joel South

Tue, March 24, 2026 astatine 9:52 AM CDT 4 min read

Pfizer (PFE) is trading astatine $26.59 with shares up 9.31% year-to-date, portion Guggenheim raised its terms people to $36 with a Buy standing versus Wall Street’s cautious $28.14 consensus. Pfizer’s oncology conception generated $4.435B successful Q4 2025, up 9% year-over-year, with cardinal franchises Vyndaqel astatine $1.688B and Eliquis astatine $2.020B delivering dependable currency generation.
Guggenheim’s bull lawsuit hinges connected a affirmative MEVPRO-1 Phase 3 readout for mevrometostat successful metastatic castration-resistant prostate crab expected successful H2 2026, which offers a 2-to-1 upside-to-downside payoff portion Pfizer’s pipeline breadth with 20 pivotal proceedings starts planned for 2026 reduces dependence connected immoderate azygous readout.
Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin discontinue earlier than expected.

Pfizer (NYSE:PFE) has softly built momentum successful 2026, with shares up 6.61% year-to-date and 2.70% implicit the past year. The banal is presently trading adjacent $26.84 but remains good beneath its 52-week precocious of $27.94. Wall Street statement sits astatine a cautious mean terms people of $28.14, reflecting a predominantly Hold posture crossed 28 expert ratings.

Against that backdrop, Guggenheim stands out: The steadfast contiguous raised its terms people from $35 to $36 portion reiterating a Buy rating, implying important upside from existent levels, good supra the Street statement of $28.14. But tin PFE realistically scope $36 by year-end?

Guggenheim's thesis rests connected a binary catalyst: Topline information from Pfizer's MEVPRO-1 Phase 3 proceedings of mevrometostat successful second-line and aboriginal metastatic castration-resistant prostate crab (mCRPC) is expected to work retired successful the 2nd fractional of 2026. The risk/reward is asymmetric successful the bull's favor: Guggenheim sees astir $2 per stock of imaginable upside connected a palmy readout versus astir $1 of downside connected failure. That 2-to-1 payoff profile, layered connected an already-recovering halfway business, makes this a intimately watched setup heading into the 2nd fractional of 2026.

Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin retire earlier than expected.

Oncology momentum: Pfizer's oncology conception generated $4.435 cardinal successful Q4 2025, up 9% year-over-year, with Padcev up 15%, Lorbrena up 46%, and oncology biosimilars up 77%. A MEVPRO-1 triumph would widen this runway into the adjacent decade, adding a caller prostate crab franchise to an already increasing portfolio.
Non-COVID basal business: The non-COVID portfolio delivered 9% operational gross maturation successful Q4 2025, anchored by Vyndaqel astatine $1.688 cardinal and Eliquis astatine $2.020 billion. This dependable currency procreation supports the 6.41% dividend output astatine existent prices, oregon 43 cents per stock quarterly.
Pipeline depth: Pfizer has guided for astir 20 pivotal proceedings starts successful 2026, including 10 obesity assets from its Metsera acquisition and 4 starts for its PD-1 x VEGF bispecific. This breadth limits dependence connected immoderate azygous readout and creates aggregate shots astatine re-rating the stock.